Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
E-pub ahead of print

Neurotensin secretion after Roux-en-Y gastric bypass, sleeve gastrectomy, and truncal vagotomy with pyloroplasty

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Colonic motility in patients with type 1 diabetes and gastrointestinal symptoms

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. How does meal composition influence the evaluation of gastrointestinal motility measured by the wireless motility capsule?

    Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

  3. Gastrointestinal motility in patients with end-stage renal disease on chronic hemodialysis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Regional gastrointestinal pH profile is altered in patients with type 1 diabetes and peripheral neuropathy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Plasma GDF15 levels are similar between subjects after bariatric surgery and matched controls and are unaffected by meals

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. MECHANISMS IN ENDOCRINOLOGY: The physiology of neuronostatin

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

Vis graf over relationer

OBJECTIVE: Neurotensin (NT) is released from enteroendocrine cells and lowers food intake in rodents. We evaluated postprandial NT secretion in humans after surgeries associated with accelerated small intestinal nutrient delivery, and after Roux-en-Y gastric bypass (RYGB) when glucagon-like peptide-1 (GLP-1) signalling and dipeptidyl peptidase 4 (DPP-4) were inhibited, and during pharmacological treatments influencing entero-pancreatic functions.

METHODS: We measured NT concentrations in plasma from meal studies: (I) after truncal vagotomy with pyloroplasty (TVP), cardia resection +TVP (CTVP), and matched controls (n = 10); (II) after RYGB, sleeve gastrectomy (SG), and in matched controls (n = 12); (III) after RYGB (n = 11) with antagonism of GLP-1 signalling using exendin(9-39) and DPP-4 inhibition using sitagliptin; (IV) after RYGB (n = 11) during a run-in period and subsequent treatment with, sitagliptin, liraglutide (GLP-1 receptor agonist), verapamil (calcium antagonist), acarbose (alpha glucosidase inhibitor), and pasireotide (somatostatin analogue), respectively.

RESULTS: (I) NT secretion was similar after TVP/CTVP (p = 0.9), but increased vs. controls (p < 0.0001). (II) NT secretion was increased after RYGB vs. SG and controls (p < 0.0001). NT responses were similar in SG and controls (p = 0.3), but early postprandial NT concentrations were higher after SG (p < 0.05). (III) Exendin (9-39) and sitagliptin did not change NT responses vs placebo (p > 0.2), but responses were lower during sitagliptin vs. exendin(9-39) (p = 0.03). (IV) Pasireotide suppressed NT secretion (p = 0.004). Sitagliptin tended to lower NT secretion (p = 0.08). Liraglutide, verapamil, and acarbose had no effect (p > 0.9).

CONCLUSION: Neurotensin secretion is increased after surgeries associated with accelerated gastric emptying and lowered by pasireotide.

OriginalsprogEngelsk
Artikelnummere14210
TidsskriftNeurogastroenterology and Motility
ISSN1350-1925
DOI
StatusE-pub ahead of print - 11 aug. 2021

ID: 67245640